PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pacira BioSciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$36.34+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.46B
- P/E (TTM)
- 103.8
- Dividend yield
- –
Pacira BioSciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $742.78M | $732.64M | $722.85M | $713.23M | $702.92M | $698.96M | $697.19M | $689.70M | $685.56M | $678.64M | $672.25M | $664.07M | 99.5% | +5.7% |
| EXPAREL | $586.78M | $581.88M | $575.13M | $567.02M | $559.13M | $553.06M | $548.96M | $545.20M | $541.87M | $540.14M | $538.12M | – | 78.6% | +4.9% |
| ZILRETTA | $121.38M | $120.06M | $116.63M | $116.78M | $116.22M | $115.59M | $118.09M | $113.67M | $114.05M | $112.60M | $111.10M | $110.36M | 16.3% | +4.4% |
| iovera | $26.45M | $25.23M | $24.18M | $23.63M | $22.82M | $22.91M | $22.81M | $22.40M | $22.00M | $20.71M | $19.69M | $18.21M | 3.5% | +15.9% |
| Bupivacaine liposome injectable suspension | $8.18M | $5.47M | $6.91M | $5.80M | $4.76M | $7.40M | $7.32M | $8.42M | $7.64M | $5.18M | $3.34M | $3.25M | 1.1% | +71.9% |
| Royalty revenue | $3.38M | $2.23M | $3.56M | $3.56M | $2.93M | $3.82M | $3.78M | $5.26M | $4.75M | $3.12M | $2.73M | $1.62M | 0.5% | +15.3% |
By region
From the segment and revenue-disaggregation notes of Pacira BioSciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.